Related Experiment Videos
Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study
C Regamey1, C Steinbach-Lebbin
1Clinique Médicale, Hôpital Cantonal, Switzerland.
Abstract:
In this open prospective clinical trial of iv ofloxacin, 87 patients were treated for severe bacterial infections. Overall results showed a clinical cure rate of 75% and 79/87 87 patients improved. 86% of causative organisms (all sensitive to ofloxacin) were eliminated. The best results were obtained in urinary tract infections where all 30 patients were clinically cured and 27 organisms (Escherichia coli, group D streptococcus, Proteus mirabilis and Klebsiella pneumoniae) were eliminated. Rapid clinical cure was observed in five patients with prostatitis. Good results were seen in arthritis and osteomyelitis. Less than three days of parenteral therapy were required before improvement was seen in patients presenting with severe enterocolitis. Ofloxacin treatment was used for the treatment of lower respiratory tract infections in 35 patients. Clinical improvement was noted in 28 patients. Five patients had unsatisfactory responses, mainly due to underlying diseases. There were two failures, both in pneumococcal pneumonia. Three minor side effects were recorded. Ofloxacin can be given for severe bacterial infections due to Enterobacteriaceae, other Gram-negative rods and other sensitive organisms. It can be given in penicillin allergic patients but it should not be used in pneumococcal pneumonia.
Insights
Intravenous ofloxacin effectively treated severe bacterial infections in 87 patients, achieving a 75% clinical cure rate. Ofloxacin demonstrated high efficacy in urinary tract infections and was well-tolerated, with few side effects observed.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Severe bacterial infections pose significant treatment challenges.
- Intravenous (IV) antibiotics are crucial for managing serious infections.
- Ofloxacin is a fluoroquinolone antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous ofloxacin in treating severe bacterial infections.
- To determine clinical cure rates and organism elimination in various infection types.
- To assess the tolerability of ofloxacin in a diverse patient population.
Main Methods:
- An open prospective clinical trial was conducted.
- Eighty-seven patients with severe bacterial infections received IV ofloxacin.
- Clinical outcomes, organism elimination, and side effects were monitored.
Main Results:
- A 75% clinical cure rate was achieved across all severe bacterial infections.
- Ofloxacin demonstrated excellent results in urinary tract infections (100% cure rate).
- High rates of causative organism elimination (86%) were observed, with rapid improvement in prostatitis and enterocolitis.
Conclusions:
- Intravenous ofloxacin is an effective treatment for severe bacterial infections, particularly urinary tract infections.
- Ofloxacin is a viable option for penicillin-allergic patients but should be avoided in pneumococcal pneumonia.
- The drug is generally well-tolerated, with a low incidence of minor side effects.